Immuto Scientific Identifies New Targets for KRAS-Mutant Colorectal Cancer Using Structural Surfaceomics
Rapid Read

Immuto Scientific Identifies New Targets for KRAS-Mutant Colorectal Cancer Using Structural Surfaceomics

What's Happening? Immuto Scientific, an AI-enabled therapeutics company, has presented preclinical findings identifying 16 potential cell-surface targets for KRAS-mutant colorectal cancer (CRC) using its structural surfaceomics platform. This research, conducted in collaboration with the University
AI Generated
This may include content generated using AI tools. Glance teams are making active and commercially reasonable efforts to moderate all AI generated content. Glance moderation processes are improving however our processes are carried out on a best-effort basis and may not be exhaustive in nature. Glance encourage our users to consume the content judiciously and rely on their own research for accuracy of facts. Glance maintains that all AI generated content here is for entertainment purposes only.